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Each of the 30 human amyloid diseases is associated with the
aggregation of a particular precursor protein into amyloid fibrils. In
transthyretin amyloidosis (ATTR), mutant or wild-type forms of the
serum carrier protein transthyretin (TTR), synthesized and secreted
by the liver, convert to amyloid fibrils deposited in the heart and
other organs. The current standard of care for hereditary ATTR is
liver transplantation, which replaces the mutant TTR gene with the
wild-type gene. However, the procedure is often followed by car-
diac deposition of wild-type TTR secreted by the new liver. Here we
find that amyloid fibrils extracted from autopsied and explanted
hearts of ATTR patients robustly seed wild-type TTR into amyloid
fibrils in vitro. Cardiac-derived ATTR seeds can accelerate fibril for-
mation of wild-type and monomeric TTR at acidic pH and under
physiological conditions, respectively. We show that this seeding
is inhibited by peptides designed to complement structures of TTR
fibrils. These inhibitors cap fibril growth, suggesting an approach
for halting progression of ATTR.
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Amyloid diseases are characterized by the tissue deposition ofproteins, synthesized as soluble precursors, as insoluble
amyloid fibrils, frequently at a distance from the site of synthesis.
Amyloid fibrils are robust fibrillar structures with the potential to
nucleate subsequent fibril formation of the soluble parental pro-
tein. In this process, known as “amyloid seeding," fibril for-
mation is accelerated by the presence of substoichiometric
quantities of preformed fibrils. Numerous laboratories have
studied and reproduced seeding of several amyloid precursors
involved in both localized and systemic amyloidoses (1–4).
However, despite clinical evidence suggesting that seeding of
the amyloid protein transthyretin (TTR) occurs in vivo (5), the
demonstration of seeding in vitro or in mouse models has not
yet been achieved. Here we investigate amyloid seeding of TTR
fibril formation using fibrils extracted from diseased human
cardiac tissue.
TTR amyloidosis (ATTR) is caused by amyloid deposition of
fibrils derived from the serum protein TTR (6–10). In hereditary
ATTR, autosomal-dominant mutations destabilize the TTR tet-
ramer, accelerating pathological aggregation and the onset of the
disease (11, 12). Although more stable than most mutant forms,
wild-type TTR is also found in amyloid deposits in both wild-type
(13–15) and hereditary (15–17) ATTR. These deposits of TTR
fibrils are found in virtually every tissue of the body and cause
peripheral neuropathies and cardiomyopathies. However, the
pathological mechanism is not fully understood. Studies of
recombinant TTR aggregates have suggested the involvement of
oligomeric intermediates in TTR cytotoxicity and subsequent
pathogenicity (18).
Cardiac ATTR pathology manifests two distinct patterns (19).
Type A cardiac ATTR is associated with the development of
progressive infiltrative cardiomyopathy, with large, diffuse, tightly
packed amyloid deposits that contain short fibrils comprised of
both full-length TTR fibrils and C-terminal TTR fragments. In
type B cardiac ATTR, more distinct amyloid deposits made of
full-length TTR fibrils surround individual muscle cells. Although
the understanding of their clinical and pathological significance is
incomplete, there is a clear distinction between subtypes: type A
deposits display a higher capacity to recruit wild-type TTR (16). If
untreated, both subtypes of TTR deposition lead to organ failure
and eventual death.
Since the liver is the main source of TTR production, beginning
in 1990, patients with hereditary ATTR have been treated by liver
transplantation, a crude form of gene therapy that replaces the
mutant ttr gene with the wild-type gene (20). Many ATTR cases
have shown prolonged life with stabilization or slowing of disease
progression after transplantation, with most favorable results
found for ATTR-V30M neuropathic patients at early stages (21).
However, this procedure is sometimes followed by progressive
cardiac deposition and death (5). Several clinical studies report
that cardiac amyloid isolated from patients after liver trans-
plantation has a predominance of wild-type over variant TTR,
suggesting that wild-type TTR can be incorporated into cardiac
amyloid, presumably by a process of seeding (5, 17, 22, 23).
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Amyloid primary nucleation, which precedes fibril formation in
the absence of seeds, is driven by specific protein segments that are
the adhesive parts of amyloid proteins (24). In previous work we
found that two TTR adhesive segments are the principal drivers of
protein aggregation in vitro. These are the segments that form the F
and H β-strands in the native TTR structure. These strands become
exposed to solvent upon TTR dissociation to monomers, enabling
their stacking into the steric zipper spines of amyloid fibrils (25, 26).
Based on the structures of the amyloid fibrils formed by these two
segments, we generated peptides designed to block fibril formation
by capping the tips of TTR fibrils (25).
Here we studied amyloid seeding of ATTR fibril formation
and found that amyloid fibrils extracted from ex vivo ATTR
cardiac tissues can seed fibril formation of both wild-type and
mutant TTR in vitro. Moreover, we find that optimized peptide
inhibitors block this seeding. Our results point to the clinical
importance of amyloid seeding in cardiac amyloidosis and pro-
pose inhibition of amyloid seeding as a promising therapeutic
strategy for ATTR.
Results
Ex Vivo Material Extracted from ATTR-D38A Cardiac Tissue Accelerates
Fibril Formation of Tetrameric TTR at Acidic pH in Vitro.We extracted
amyloid fibrils from the explanted heart of a hereditary ATTR
patient carrying the ATTR-D38A mutation (SI Appendix, Table
S1). Our procedures for extraction and characterization are
outlined in SI Appendix, Fig. S1A. Before extraction, we confirmed
the amyloid content of the explanted heart by Congo red and
immunostaining of paraffin-embedded sections of the organ (SI
Appendix, Fig. S1 B and C). Sections stained with Congo red
displayed streaks of apple-green birefringence (SI Appendix, Fig.
S1B). Tissue immunostaining revealed the presence of scattered
patches of TTR deposits throughout the sample (SI Appendix, Fig.
S1C). Amyloid extraction was performed on a frozen piece of the
same organ by the protocol of Westermark et al. (27), using
multiple cycles of homogenization with saline and water. We
confirmed the presence of both short and long amyloid-like fibrils
in the resultant resuspension by transmission electron microscopy
(TEM) (SI Appendix, Fig. S1D). The enrichment of TTR fibrils in
the extract was confirmed by anti-TTR Western blot, size-exclu-
sion chromatography, and mass spectrometry-based protein se-
quencing (SI Appendix, Fig. S1 E and F and Dataset S1).
We next found that ex vivo amyloid material seeds soluble
TTR into fibrils at acidic pH. We define seeds as ex vivo material
obtained from ATTR patients that can accelerate recombinant
TTR fibril formation. Ex vivo ATTR seeds were obtained by
sonicating the resuspended fibrils. Small fibrils of various lengths
were observed by TEM (SI Appendix, Fig. S1A). Total protein
concentration was measured, and 30 ng/μL ex vivo seeds were
added to 0.5 mg/mL native recombinant wild-type TTR (Fig.
1A). We added ATTR seeds at two different time points—at
initiation or after 22 h of incubation—to evaluate the aggrega-
tion and formation of thioflavin T (ThT)-positive species of
recombinant wild-type TTR before adding the seeds. The TTR
tetramer must undergo rate-limiting dissociation before fibril
formation (28). To render tetramer dissociation fast, we per-
formed this assay at pH 4.3, and fibril formation was monitored
by ThT fluorescence at 37 °C with constant orbital shaking.
Whereas ex vivo seeds alone did not result in a substantial in-
crease in ThT signal, the addition of seeds at either the initial or
the 22-h time point resulted in a rapid increase in fluorescence
(Fig. 1A). Increased fluorescence correlated with the accumu-
lation of protein aggregates as visualized by optical microscopy
(SI Appendix, Fig. S2A) and the appearance of fibrillar structures
visible by TEM (Fig. 1B). In contrast, wild-type recombinant
TTR does not generate aggregates at a concentration of 0.5 mg/mL
after 24 h of incubation when ATTR seeds are not present
(Fig. 1 B–D). Higher concentrations and longer incubation times
are required for the generation of protein aggregates under these
conditions (Fig. 1B). This seeding effect was dependent on TTR
concentration, since the gradual addition of recombinant protein
(0–1 mg/mL) to a fixed amount of seeds (30 ng/μL) results in a
gradual increase in fibril formation (SI Appendix, Fig. S2B).
ATTR Seeds Accelerate Fibril Formation of both Wild-Type and Mutant
TTR Variants in a Dose-Dependent Manner. Two forms of recombi-
nant TTR were studied for this assay: wild-type TTR and the
variant D38A mutant, at pH 4.3. Both forms are tetrameric in
solution at pH 7.4 (SI Appendix, Fig. S2C). The addition of in-
creasing amounts of seeds to wild-type or D38A recombinant
TTR resulted in a dose-dependent increase in ThT signal after a
brief lag phase of 10–20 min (Fig. 1 C and D and SI Appendix,
Fig. S2 D and E). Neither recombinant TTR in the absence of ex
vivo seeds nor ATTR seeds in the absence of protein caused an
increase in ThT signal (Fig. 1 C and D and SI Appendix, Fig. S2 F
and G). We confirmed that the resultant fibrils were derived by
de novo fibril formation from recombinant protein as follows.
First, we obtained the insoluble fraction of the samples by cen-
trifugation and resuspension in guanidinium hydrochloride.
These fractions were spotted onto a nitrocellulose membrane for
immuno-dot blot analysis with an antibody that recognizes the
histidine tag of recombinant protein. We found seed-dependent
enhancement of recombinant TTR content in the insoluble
fraction (Fig. 1 C and D, Right Insets), consistent with an increase
in absorbance at 280 nm (SI Appendix, Fig. S2H). As expected,
the increase in insoluble material was accompanied by a gradual
decrease of soluble TTR, as detected by BCA protein assay (Fig.
1E) and anti–His-tag Western blot (SI Appendix, Fig. S2I). We
could not detect any remaining soluble protein after 24 h in-
cubation with seeds at 30 ng/μL or higher (Fig. 1E). We observed
that the soluble fraction depletes faster than the ThT-positive
species appear (Fig. 1E vs. Fig. 1 C and D, respectively). We
reason that, at low seed concentrations, the sample may contain
both highly ordered and less well-ordered assemblies. Taken
together, these results suggest that ex vivo extracts obtained from
ATTR-D38A cardiac tissue can accelerate fibril formation of
recombinant wild-type and D38A TTR at acidic pH where tet-
ramer dissociation is fast.
Amyloid Seeding Is Caused by the TTR Fibrillar Content of ex Vivo
Extracts and Not by Other Coextracted Insoluble Material. We first
observed that sonication greatly potentiates TTR amyloid seed-
ing, suggesting the involvement of fibril tips in templating TTR
fibril formation (Fig. 1F). In addition, immunodepletion of ex
vivo extracts of TTR reduced their capacity to seed recombinant
wild-type TTR (SI Appendix, Fig. S3 A and B). TTR was se-
quentially removed from the ex vivo extract by several cycles of
binding to an anti-TTR surface. The seeding capacity diminishes
as TTR is gradually removed from the extract. As an additional
control, we obtained cardiac tissue explanted after ATTR-
unrelated heart failure (SI Appendix, Table S1). We confirmed
the absence of amyloid TTR deposits by Congo red and immu-
nostaining of tissue sections (SI Appendix, Fig. S3 C and D).
After performing the saline-water extraction described above, we
evaluated TTR content in the extract by anti-TTR dot blot (SI
Appendix, Fig. S3E) and confirmed the absence of amyloid fibrils
by TEM (SI Appendix, Fig. S3F). We then performed an amyloid
seeding assay and found that non-ATTR ex vivo extract does not
accelerate native recombinant TTR fibril formation (SI Appen-
dix, Fig. S3G). Together these findings suggest that amyloid
seeding of recombinant TTR is caused by fibrillar TTR-derived
material found in ATTR cardiac tissue and not by other in-
soluble material extracted from cardiac specimens, such as col-
lagen (SI Appendix, Fig. S3F).
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Under Physiological Conditions, ATTR-D38A Cardiac Seeds Also Accelerate
Fibril Formation of TTR When Monomerized by Mutagenesis. In seeking
to evaluate amyloid seeding of ATTR fibrils under physiological
conditions, we chose to work with a monomeric variant of TTR
engineered by Kelly and coworkers (29), herein referred to as
“MTTR” (25). This variant carries the double mutation F87M/
L110M, is soluble after purification, and displays faster aggre-
gation than wild-type TTR or familial mutants because it by-
passes the time requirement for tetramer dissociation (29). Kelly
and coworkers (30) found that, when subjected to low pH,
MTTR unfolds into an amyloidogenic variant that nucleates into
aggregates in a process that is not affected by the presence of
seeds. In that study, seeds were prepared by aggregation of
MTTR at low pH in vitro. We wondered whether seeds obtained
from ATTR patients differ from those originating in vitro. We
evaluated the seeding capacity of ATTR-D38A fibrils with
recombinant tetrameric and monomeric TTR at physiological
and acidic pH. We followed amyloid fibril formation by ThT
fluorescence, protein quantification, anti–His-tag dot blot of in-
soluble fractions, and TEM, as described above (Fig. 2). Con-
sistent with our results in Fig. 1, wild-type TTR aggregation was
accelerated by ATTR seeds at pH 4.3 (Fig. 2). We also found
that the addition of ATTR seeds to MTTR at pH 7.4 resulted in
the formation of ThT-positive species (Fig. 2A). However, the
addition of these seeds to recombinant wild-type TTR did not
show a significant effect when tested at physiological pH (Fig.
2A), suggesting that seeded fibril formation requires the disso-
ciation of tetramers into monomers. This hypothesis is supported
by the observation that ATTR-D38A seeds are capable of con-
verting MTTR into ThT-positive species under physiological
conditions with a lag phase of 4–5 h (Fig. 2A). Under these
conditions, TEM analysis revealed that 24 h of incubation of
MTTR with ATTR seeds resulted in elongated amyloid-like fi-
brils (Fig. 2C). For completeness we note that MTTR aggregated
under acidic conditions in the absence of ATTR seeds, but these
aggregates were ThT-negative and appear as amorphous, non-
fibrillar structures when analyzed by TEM (Fig. 2 A and C). The
addition of seeds to MTTR at pH 4.3 resulted in the formation of
ThT-positive species, but no lag phase was observed, similar to
recombinant wild-type TTR in the presence of seeds at pH 4.3
(Fig. 2 A and C). We did not find significant differences in the
seeding capacity of seeds that were preincubated at pH 4.3 vs.
pH 7.5 when added to MTTR. Taken together, our results sug-
gest that ATTR-D38A seeds accelerate monomeric TTR fibril
formation under physiological conditions.
Seeded TTR Fibrils Exhibit Molecular Properties in Common with
Amyloid Fibrils. The analysis of the ThT fluorescence spectrum
of individual fibril samples shows that the affinity of ThT is
greatest for ATTR fibrils, followed in order by MTTR seeded
fibrils, wild-type TTR seeded fibrils, and D38A seeded fibrils
(Fig. 3A). In contrast, protein aggregates obtained from un-
seeded wild-type TTR after 4 d of incubation at pH 4.3 did not
present any significant affinity for ThT (Fig. 3A). We also found
that ATTR fibrils and seeded fibrils exhibit birefringence when
stained with Congo red, but wild-type TTR aggregates do not
(Fig. 3B). Moreover, seeded TTR fibrils and ATTR fibrils both
display a cross-β diffraction pattern when analyzed by X-rays
(Fig. 3C). The diffraction patterns of both fibrils exhibit the
two characteristic strong reflections of amyloid: the reflection at
4.7 Å that results from the stacking of β-strands along the fibril
and the reflection at near 11 Å that results from the mating of
adjacent β-sheets (Fig. 3C and SI Appendix, Fig. S4A and Table
S2). In addition, we found that, similar to ex vivo fibrils, seeded
fibrils obtained by the addition of ATTR-D38A seeds to wild-type
TTR or MTTR also accelerate fibril formation of both wild-type
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Fig. 1. Amyloid seeding at pH 4.3 of wild-type TTR
by ex vivo ATTR seeds extracted from the explanted
heart of an ATTR-D38A patient. (A) Amyloid seeding
assay of recombinant wild-type TTR when 30 ng/μL
ATTR-D38A ex vivo seeds were added at 0 h and after
22 h of preincubation, as monitored by ThT fluores-
cence. (B) Electron micrograph of aggregates of wild-
type TTR after 24 h (i and iii) or 4 d (ii and iv) of in-
cubation. ATTR seeds were added at 0 h (i and ii).
(Scale bars, 100 nm.) (C and D) Amyloid seeding as-
says monitored by ThT fluorescence. Increasing
amounts of ATTR-D38A ex vivo seeds were added at
time 0 to recombinant wild-type TTR (C) or D38A TTR
(D). (Right Insets) Anti–His-tag immuno-dot blot of
insoluble fractions (IF). (E) Protein concentration in
the soluble fraction extracted from C and D, mea-
sured by BCA protein assay. The dashed line marks
the initial protein concentration (0.5 mg/mL). (F) The
280-nm absorbance of insoluble fractions collected
from an amyloid seeding assay of recombinant wild-
type TTR with and without 30 ng/L sonicated or
nonsonicated seeds. n = 3; error bars indicate SD. AU,
absorbance units; a.u., arbitrary units; N/A, not ap-
plicable. In A, C, and D all replicates are shown.
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TTR and MTTR (Fig. 3D), suggesting that the conformation
of the ex vivo fibrils is encoded in the products of our fibril
formation assay.
ATTR ex Vivo Fibrils Carrying Various Genotypes also Seed Wild-Type
TTR Fibril Formation.We extracted ex vivo fibrils from the cardiac
tissues of seven additional ATTR patients and found that they
also were capable of seeding fibril formation of wild-type TTR
under partially denaturing conditions (Fig. 4). Among these
patients, there were three cases of wild-type amyloidosis and four
cases of hereditary amyloidosis other than ATTR-D38A (SI
Appendix, Table S1). All patients presented advanced amyloid-
osis symptomatology or were deceased as a consequence of
ATTR. The tissue specimens came from either explanted or
autopsied hearts. We confirmed the presence of amyloid-like
fibrils by TEM after the extraction (SI Appendix, Fig. S5A).
We also confirmed TTR content in the resultant fibril resus-
pension by Western blot and mass spectrometry sequencing (SI
Appendix, Fig. S5 B and C and Dataset S1). The addition of these
ex vivo seeds to wild-type TTR under acidic conditions resulted
in the formation of ThT-positive species, as observed for ATTR-
D38A ex vivo seeds (Fig. 4A).
We next analyzed whether amyloid seeding capacity correlates
with any cardiac pathology subtype, gender, or age, three factors
previously associated with ATTR severity (31–33). The presence
of fragmented TTR, present in type A cardiac amyloidosis, was
evaluated by Western blot using an antibody that specifically
recognizes TTR C-terminal fragments (SI Appendix, Fig. S5B).
With the exception of ATTR-T60A, we observed an apparent
correlation between seeding capacity and fragmented TTR
content, with a Pearson correlation coefficient of 0.96 (Fig. 4B).
We did not observe correlation with ATTR patient age or gender
in our assays (Fig. 4C); detecting such a correlation, if one exists,
may require a larger cohort.
Amyloid Seeding Can Be Halted by Peptide Inhibitors of TTR
Aggregation. In our previous study, we identified β-strands F
and H of native TTR as driving TTR amyloid aggregation in
vitro (25). From the atomic structures of these strands in their
amyloid forms, we designed two 16-residue peptides intended
to cap fibrils of the F and H strands. Together these two peptides
were able to reduce fibril formation of wild-type recombinant
TTR. In the present work, we optimized these peptides by re-
ducing their amyloidogenicity without compromising their inhib-
iting activity, as detailed in Materials and Methods and SI
Appendix, Fig. S6. All evaluated sequences including both orig-
inal and optimized peptides are listed in SI Appendix, Table S3.
We then evaluated the effectiveness of the best-scored inhibitors
in our seeding assays (SI Appendix, Fig. S6B and Table S3) and
found that two optimized peptides arrested TTR fibril formation
more efficiently than our earlier inhibitors (Fig. 5A and SI Ap-
pendix, Fig. S6B). Both the original and optimized peptide in-
hibitors are named as “Tab” (transthyretin aggregation blockers)
followed by the letters F and/or H referring to the target strand(s).
The name ends with a number that depends on whether the
peptide was obtained in the original design (number 1) (25) or
was optimized in the present work (number 2). For instance,
TabF1 corresponds to the peptide inhibitor that targets strand F
as described by Saelices et al. (25), and TabFH2 refers to a
mixture of the two optimized peptide inhibitors that target
strands F (TabF2, RRRRHVAHPFV-N-me-Glu-FTE) and H
(TabH2, RRRRSYVTNPTSY-N-me-Ala-VT) designed and char-
acterized in this study (SI Appendix, Table S3). We evaluated
these inhibitors in our amyloid seeding assay containing 0.5 mg/mL
recombinant wild-type TTR (∼35 μM) and 30 ng/μL ATTR-
D38A seeds in the presence or the absence of 180 μM peptide
inhibitors. We found that targeting strand H is more effective
than targeting strand F (Fig. 5A). Nonetheless, the combination
of peptide blockers for both strands F and H, TabFH2, resulted
in full inhibition of seeding from ex vivo ATTR-D38A fibrils
(Fig. 5A). The inhibiting activity of TabFH2 was found to be
dose dependent (SI Appendix, Fig. S7). In contrast, the addition
of 180 μM diflunisal or tafamidis did not inhibit amyloid seeding
under the same conditions (SI Appendix, Fig. S8A). Preincubation
of TTR with the stabilizing compounds for 22 h did not affect
this outcome (SI Appendix, Fig. S8B). Others have shown that
the presence of these compounds at similar concentrations fully
inhibits aggregation of recombinant TTR at acidic pH in the
absence of seeds (34, 35). Finally, TabFH2 was found to be ef-
ficient at halting amyloid seeding of MTTR under physiological
conditions (Fig. 5B). Inhibition of amyloid seeding was con-
firmed by TEM (Fig. 5C).
Discussion
Seeding in Amyloid Disease. The importance of seeding for con-
version of soluble proteins to pathogenic amyloid fibrils was first
recognized by Ranlov and coworkers (36–39) in the late 1960s,
followed by Robert Kisilevsky and coworkers (4, 40–42) begin-
ning in the late 1970s. They described the so-called “amyloid
enhancing factor” in a mouse model of AA amyloidosis, which
they defined as a transferable activity that reduces the induction
time of splenic deposition of the amyloid protein. Later, the
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Fig. 2. Amyloid seeding of monomeric TTR by ex vivo ATTR-D38A seeds
under physiological conditions. (A) Amyloid seeding assay followed by ThT
fluorescence. ATTR-D38A ex vivo seeds (30 ng/μL) were added to recombi-
nant wild-type (rec, WT) TTR or MTTR at pH 4.3 or 7.4, as labeled. All rep-
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units. (Bottom Insets) Anti–His-tag immuno-dot blot of insoluble fractions.
(C) Electron micrographs of MTTR aggregates obtained at pH 4.3 and pH 7.4.
(Scale bars, 200 nm.)
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pioneering study of Jarrett and Lansbury recognized the role of
seeding in the progression and transmission of other amyloid
diseases (43) by demonstrating that introduction of a seed—a
preformed amyloid fibril—into a solution of the same dissolved
but supersaturated protein nucleates the formation of identical
amyloid fibrils (44–46). In vitro experiments have shown that
tissues extracted from the autopsied brains of Alzheimer’s pa-
tients accelerate the aggregation of dissolved β-amyloid (47, 48).
In a dramatic demonstration of the power of amyloid seeding,
serial in vitro seeding has been developed into a method of
amplifying infectious prion fibrils (49, 50).
In vivo amyloid seeding has been proposed to be the mecha-
nism of spreading from cell to cell of amyloid fibrils associated
with neurodegenerative diseases (51–54). For example, the in-
jection of fibrils of amyloid-β, tau, or α-synuclein into the brains
of animals has been shown to induce the formation of inclusions
at the injection sites, from which they spread to distant regions of
the brain, presumably by a mechanism of seeding (2, 55, 56).
Amyloid seeding may also account for the iatrogenic trans-
mission of Creutzfeldt–Jakob disease (CJD) via cornea trans-
plant, contaminated neurosurgical instruments, blood products
from CJD patients, or contaminated growth hormone (57).
In short, amyloid seeding appears to be a potent mechanism of
amplification and spread of disease-related fibrils. However,
despite clinical evidence of amyloid seeding of TTR in vivo,
demonstration of TTR amyloid seeding has remained elusive in
the laboratory. Here we have investigated the potential of ex vivo
fibrils extracted from ATTR patients to seed recombinant TTR
in vitro and its inhibition by structure-based peptide inhibitors.
Potent Power of Seeds Extracted from ATTR Patients. The first of
our two principal findings is that insoluble material containing
amyloid fibrils of TTR, extracted from cardiac tissues of ATTR
patients (SI Appendix, Figs. S1 and S5), seeds both wild-type and
familial variants of TTR into amyloid fibrils (Fig. 1). Table 1
summarizes the relevant experiments and controls. At pH 4.3,
where acid destabilizes the native tetrameric structure of TTR,
forming monomers and thereby exposing the amyloid-driving
segments of β-strands F and H, the ATTR-extracted seeds
cause immediate aggregation into TTR amyloid fibrils. Under
the same conditions in the absence of these seeds, we observe the
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Fig. 3. Characterization of fibrils obtained from
wild-type TTR and MTTR by amyloid seeding. (A) ThT
spectra of 0.25 mg/mL TTR fibrils and aggregates.
Samples were obtained from recombinant wild-type,
D38A, or MTTR variants when incubated with ATTR-
D38A ex vivo seeds for 24 h. MTTR seeded fibrils
were obtained at pH 7.4; D38A and wild-type TTR-
seeded fibrils were obtained at pH 4.3. Protein ag-
gregates were obtained from 1 mg/mL recombinant
wild-type TTR incubated for 4 d at pH 4.3 in the ab-
sence of seeds. a.u., arbitrary units. (B) Congo red
staining of TTR fibrils and aggregates analyzed in A
and visualized by optical microscopy under fluores-
cence [540-nm filter, colored in green for better
contrast (Bottom), bright-field (Middle), and polar-
ized light (Top)]. (Scale bars, 100 μm.) (C) X-ray dif-
fraction of ex vivo seeds (i) and fibrils obtained from
wild-type TTR (ii) and MTTR (iii) when incubated
with ATTR-D38A for 24 h at pH 4.3 and 7.4, re-
spectively. Open and closed arrowheads point to
4.7-Å and ∼11-Å reflections, respectively. (D) Amy-
loid seeding assay of 0.5 mg/mL TTR variants by the
addition of several fibril samples. MTTR*, fibrils
obtained after incubation of 0.5 mg/mL MTTR with
ATTR-D38A seeds for 24 h at pH 7.4; rec. WT*, fibrils
obtained after incubation of 0.5 mg/mL recombinant
wild-type TTR with ATTR-D38A seeds for 24 h at
pH 4.3. Both MTTR and recombinant wild-type fibrils
were sonicated before this assay and were used as
seeds, as labeled. All replicates are shown; n = 3. a.u.,
arbitrary units.
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gradual formation of amorphous aggregates of TTR, as others
have observed (30, 58). The lineal increase in aggregation of
TTR, lacking the commonly observed lag phase in amyloid ag-
gregation, has been explained by others as a “downhill poly-
merization” in which monomers gradually add to growing
aggregates (30). Similar lineal formation of aggregates has been
observed for mutant MTTR either seeded by MTTR recombi-
nant aggregates or in the absence of seeds (30). In contrast, our
ATTR ex vivo seeds produce an immediate rapid formation of
MTTR amyloid at acidic pH. Apparently, the patient-extracted
ATTR seeds possess a conformation differing from recombinant
TTR fibrils that endows ATTR fibrils with potent seeding po-
tential, at least at low pH.
It is important to know if this potent seeding potential of patient-
extracted seeds operates under physiological conditions that more
accurately represent in vivo environments. Consequently, we re-
peated seeding experiments at pH 7.4 (Fig. 2 and Table 1). At this
higher pH, the seeds extracted from ATTR patients again nucleate
MTTR into amyloid fibrils. The kinetic profile in this experiment
(Fig. 2A) shows a typical amyloid lag phase shortened by seeding.
Others have shown that ThT binds to MTTR aggregates at acidic
pH with an affinity that is only 0.6% higher than physiological pH—
or baseline (29). We find that ThT binds to MTTR when seeded
both at acidic pH, with 15% binding compared with baseline, and at
physiological pH, with 91% binding compared with baseline. Taken
together, our experiments at low and physiological pH suggest that,
once ATTR forms amyloid fibrils, these have the capacity to con-
vert wild-type or variant TTR into additional amyloid fibrils upon
TTR dissociation.
Differences between ATTR fibrils and in vitro-produced TTR
aggregates may explain the lack of seeding of the latter (30, 59).
Visual inspection of species by electron microscopy shows clear
morphological differences (SI Appendix, Fig. S1D vs. Fig. 1B).
Whereas ATTR ex vivo fibrils appear as fibrillar structures, TTR
aggregates obtained in the absence of seeds appear as amor-
phous aggregates. In addition, we found that ATTR ex vivo fi-
brils exhibit higher Congo red and thioflavin T reactivity than
TTR aggregates (Fig. 3 A and B), suggesting a different supra-
molecular organization. Of special note is that the daughter fi-
brils formed by ATTR seeding can themselves seed additional
wild-type or variant TTR into amyloid fibrils (Fig. 3D). That is,
the fibril conformation that endows the fibrils extracted from
ATTR tissue with potent seeding power is transmitted by a pro-
cess of serial templating to a new generation of fibrils, conferring
affinity for Congo red and ThT as well as seeding capacity (Fig.
3D). We reason that ATTR fibrils form in an environment that
differs from in vitro conditions and that they mature after months
or years of environment exposure. The reason why other labora-
tories did not observe acceleration of TTR deposition in vivo after
the injection of ex vivo ATTR fibrils into transgenic mouse models
remains unclear (59, 60), but we note that these studies included
only a limited number of animals and conditions.
Implications of Seeding for ATTR. The powerful seeding effect of
disease-related TTR fibrils is consistent with key observations about
ATTR pathogenesis. Of particular importance, our findings provide
a potential explanation for why the treatment of liver trans-
plantation for ATTR is not always effective and sometimes results
in cardiac deposition of wild-type TTR (5, 17, 22, 23, 61, 62). Be-
cause TTR is largely biosynthesized in the liver, transplantation
with a liver that secretes wild-type TTR should replace most cir-
culating mutant TTR with wild-type TTR. However, if mutant
amyloid seeds remain in other tissues, our experiments suggest that
the seeds are able to convert the wild-type TTR provided by the
new liver to amyloid fibrils, perpetuating disease. There are also
cases of deposition of TTR amyloid bearing the donor mutation in
recipients of so-called “domino” liver transplantations (63). In this
procedure, explanted livers from patients with familial ATTR are
implanted in patients with fatal hepatic disorders. Some previous
reports propose age as a significant contributor to secondary car-
diac deposition in domino liver transplants, resulting from a com-
promised chaperoning function of the aged implanted liver (64, 65).
Although explanted livers do not contain congophilic fibrillar
structures, the presence of undetectable seeds in the explanted
livers has also been proposed to be a cause of disease transmission
in domino liver transplant recipients (66–68).
Our finding that ATTR amyloid material seeds fibril formation
of wild-type TTR (Fig. 4) illuminates other puzzling observations
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Fig. 4. Amyloid seeding by ATTR material extracted
from the hearts of eight ATTR patients. (A) Amyloid
seeding assay at pH 4.3 of wild-type recombinant TTR
in the presence of ATTR seeds extracted from the
hearts of ATTR patients with various genetic back-
grounds, monitored by ThT fluorescence. Superscripts
denote particular ATTR patients. All replicates are
shown; n = 3. a.u., arbitrary units. (B) Comparison of
amyloid seeding capacity (vertical axis) and relative
quantity of truncated TTR of ex vivo seeds. Truncated
TTR content was quantified by ImageJ from two in-
dependent Western blots. (C) Comparison of amyloid
seeding capacity (vertical axis) and ATTR patient age.
In both B and C, amyloid seeding capacity was mea-
sured as follows: 30 ng/μL seeds were incubated with
0.5 mg/mL recombinant wild-type TTR at pH 4.3, and
280-nm absorbance of the insoluble fraction collected
after seeding for 24 h was measured. Linear re-
gression and Pearson r were obtained by OriginLab.
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about ATTR pathogenesis. Although found to be more stable than
mutant variants in vitro, wild-type TTR deposits in both hereditary
and wild-type ATTR (12). Previous studies have found a correla-
tion of more rapid ATTR pathogenesis with less stable mutant
TTR variants (11). However, if the stability of TTR is the principal
factor in the formation of amyloid fibrils, it is puzzling that TTR
amyloid deposits in hereditary ATTR patients contain 30–70% of
the more stable wild-type protein (17, 61, 69, 70). However, the
presence of wild-type TTR is expected as a result of seeding of the
wild type by disease-related seeds, as shown in Figs. 1A and 4A.
In ATTR patients, TTR seeding may be affected by a variety
of factors such as age, gender, tissue type, pathology, or geno-
type. Westermark and coworkers (19) discovered two distinct
pathological patterns of amyloid deposition in ATTR patients
(9). In type A amyloidosis, TTR depositions contain, in addition
to full-length TTR, a 79-residue truncated C-terminal fragment
of TTR; in type B patients, TTR depositions contain only full-
length TTR. The type A phenotype has been found to carry a
higher risk of progressive cardiac deposition after liver trans-
plantation (16). In our analyses of ATTR cardiac seeds, six of
eight samples contained traceable amounts of fragmented TTR
(SI Appendix, Fig. S5B). We observed that, with the exception of
one ATTR case, amyloid seeding capacity correlated with the
presence of C-terminal fragments in the extract (Fig. 4B). In our
assays, neither patient gender nor age correlated with seeding
capacity (Fig. 4C). However, our limited number of specimens
does not permit definite conclusions. We are also aware that this
study does not include the evaluation of amyloid seeding in tissue
samples other than the heart. It is possible that the tissue type
may influence protein fragmentation and/or amyloid seeding. In
any case, we suggest that amyloid seeding may become patho-
logically relevant with advancing disease after amyloid nuclei are
formed from dissociated TTR.
Inhibition of TTR Fibril Formation. Our second principal finding is
that the capping of TTR amyloid fibrils by designed peptides
inhibits TTR amyloid seeding (Fig. 5). This may be of special im-
portance for cardiac ATTR patients, who are often diagnosed
when manifesting advanced TTR deposition and have limited
treatment options. The general approach of fibril capping for
amyloid inhibition has previously been shown to be effective for
blocking fibrils of other proteins: constructs of tau in vitro and
p53 in vitro and in mice (71, 72). In our previous work on in-
hibition of TTR, we used the steric zipper structures of β-strands
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Fig. 5. Inhibition of amyloid seeding by designed
peptide inhibitors. (A) ThT assay to evaluate inhibition
of seeding of ex vivo ATTR-D38A at pH 4.3 by 180 μM
designed inhibitors of TTR aggregation when added
to 0.5 mg/mL recombinant wild-type TTR. All repli-
cates are shown; n = 3. (Right Inset) Anti-TTR dot blot
of insoluble fractions. (B) Inhibition of amyloid seed-
ing of 0.5 mg/mL MTTR by 180 μM TabFH2 at physi-
ological pH, monitored by ThT fluorescence. All
replicates are shown; n = 3. (C) Electron micrographs
of samples containing TabFH2 obtained in A and B
confirming inhibition of amyloid seeding.
Table 1. Summary of relevant experiments and controls
pH Seeded material Seeds Result Data
4.3 Wild-type native TTR Extracted ATTR Immediate TTR amyloid fibrils; no lag Fig. 1 A and B
No seeds Gradual TTR amorphous aggregation Figs. 1B, 3 A and B, and 5 A and B
MTTR Extracted ATTR Immediate TTR amyloid fibrils; no lag Fig. 2A
No seeds Gradual TTR amorphous aggregation Hurshman et al. (30)
MTTR fibrils Gradual TTR amorphous aggregation Hurshman et al. (30)
7.4 Wild-type native TTR Extracted ATTR No aggregates Fig. 2
No seeds No aggregates Fig. 2
MTTR Extracted ATTR Lag, then immediate formation of amyloid
fibrils upon seeding
Figs. 2 and 3
No seeds Slow formation of amorphous aggregates Hurshman et al. (30)
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F and H to design the TabFH1 peptide blockers (25). However,
a limitation of the TabFH1 blockers is that they themselves form
fibrils at high concentration. The TabFH2 inhibitors designed in the
present study do not share this limitation and show improved
efficacy.
In summary, here we document the capacity of disease-related
seeds of TTR amyloid to convert native tetrameric wild-type TTR to
amyloid in vitro. This finding helps to explain why disease symptoms
persist in some patients even after the main source of disease-prone
TTR has been removed. Because seeding tetrameric TTR into fi-
brils in vitro requires an acidic environment not necessarily present
in vivo, further scrutiny of the relevance of these results to human
pathology is warranted. Our results also suggest that the inhibition
of the elongation of TTR fibrils by designed inhibitors may be a
plausible treatment for ATTR cases. We envision combinatory
treatments for ATTR, targeting protein expression, protein stability,
deposit clearance, and amyloid seeding (35, 73–78).
Materials and Methods
Antibodies. Antibodies used were rabbit anti-human TTR polyclonal antibody
(Western blots and dot blots, 1:10,000; immunohistochemistry, 1:2,000; ELISA,
1:4,000; DAKO, Agilent Technologies), anti–His-tag HRP-conjugated HisProbe
(dot blots, 1:10,000; Thermo Fisher Scientific), and HRP-conjugated goat anti-
rabbit IgG antibody (Western blots and dot blots, 1:5,000; immunohistochem-
istry, 1:2,000; DAKO, Agilent Technologies). Anti-truncated TTR was obtained as
a gift from Gunilla Westermark (Uppsala University, Uppsala, Sweden) (79) (la-
beled as “1898”; 1:5,000). Ig fraction from nonimmunized rabbits was used as
negative control (immunohistochemistry, 1:2,000; DAKO, Agilent Technologies).
Patients and Tissue Material. Tissues from eight ATTR patients carrying wild-
type TTR (n = 3) or TTR mutations (n = 5) were included in the study (see SI
Appendix, Table S1 for patient and tissue material characteristics). Speci-
mens from either explanted hearts or autopsy were obtained from several
laboratories. The University of California, Los Angeles Office of the Human
Research Protection Program granted exemption from Internal Review
Board review because all specimens were anonymized.
Congo Red Staining of Cardiac Tissue. Congo red staining was performed to
verify the presence of amyloid deposition in tissues. Cardiac sections10 μm
thick were deparaffinized by heating, xylene baths, and gradual hydration.
The samples were stained using the Amyloid Stain, Congo Red Kit (Sigma
Aldrich) as described by the manufacturer. Briefly, slides were incubated in a
freshly made alkaline sodium chloride solution for 30 min and then were
transferred to and incubated in an alkaline Congo red solution for another
30 min. Slides were dehydrated, mounted with Permount (Thermo Fisher
Scientific) and then were analyzed under bright-field and polarized light.
Amyloid was identified by its characteristic apple-green birefringence.
Immunohistochemistry of Cardiac Tissue. Immunostaining of 4-μm tissue sec-
tions was performed using polyclonal rabbit anti-human TTR antibodies
(DAKO, Agilent Technologies) or Ig fraction from nonimmunized rabbits as
negative control (DAKO, Agilent Technologies) diluted 1:2,000 in blocking
buffer. HRP-conjugated goat anti-rabbit IgG antibody (DAKO, Agilent
Technologies) was used diluted 1:2,000 in blocking buffer. Reactivity visu-
alization was made with the EnVision+ System/HRP, Rb (DAB+) (DAKO,
Agilent Technologies) as described by the manufacturer.
Extraction of Amyloid Material from Human Tissue. Amyloid fibrils were
extracted from fresh-frozen human tissue as described earlier (27). Briefly, 1–5 g
of amyloid-positive cardiac tissue was thawed and minced with a modular mo-
torized homogenizer in 10 mL of 0.15 M NaCl. The sample was centrifuged at
15,000 rpm for 30 min (rotor F18S-12x50y, Thermo Fisher Scientific), and the
resulting pellet was homogenized in 0.15 M NaCl and centrifuged again. This
process was repeated seven times. The pellet was further homogenized in dis-
tilled water and centrifuged three times; the final pellet was lyophilized. Amy-
loid fibril load was confirmed by TEM and X-ray fiber diffraction. TTR content
was analyzed by Western blot and liquid sample-electrospray ionization-MS/MS.
Non-ATTR cardiac control tissue was subjected to the same extraction procedure.
TEM. TTR aggregation was confirmed by TEM as described by Saelices et al.
(25). Briefly, a 2- to 5-μL sample was spotted onto freshly glow-discharged
carbon-coated grids (Ted Pella), incubated for 4 min, and then rinsed three
times with distilled water. Grids were finally negatively stained with 2%
uranyl acetate for 2 min. An FEI T12 Quick CryoEM electron microscope at an
accelerating voltage of 120 kV was used to examine the specimens. Images
were recorded digitally by a Gatan 2K×2K CCD camera.
Size-Exclusion Chromatography. A 20-μL sample containing 5 μg of sonicated
ATTR-D38A ex vivo seeds was run over a Superose 6 Increase 3.2/300
column (GE Healthcare), which separates molecules with masses between
∼5,000 and ∼5,000,000 Da, using PBS (pH 7.4) as elution buffer. Gel filtration
standard mixture was purchased from Bio-Rad.
X-Ray Fibril Diffraction. X-ray fibril diffraction patterns were collected as
described previously (80). Briefly, seeded fibrils and ex vivo extracted fibrils
were concentrated by centrifugation, washed, and oriented while drying
between two glass capillaries. The glass capillaries were mounted on a brass
pin for diffraction at room temperature using X-rays produced by a Rigaku
FR-E+ rotating anode generator equipped with a Rigaku R-AXIS HTC
imaging plate detector. Diffraction patterns were collected at a distance
of 180 mm and analyzed using the Adxv software package (81). X-ray re-
flection peaks were obtained by radial intensity averaging.
Sequencing of Proteins Contained in Patient-Derived Samples. Ex vivo seeds
were analyzed by mass spectrometry, as described elsewhere (82). Before a
trypsin digest, a chloroform/methanol precipitation was performed to pre-
cipitate the protein in the original ex vivo seeds. Four volumes of methanol,
one volume of chloroform, and three volumes of water were sequentially
added to one volume of each protein sample with vortexing after each
addition. The samples were centrifuged at 16,000 × g for 5 min, and the
aqueous supernatant was removed. The protein remained at the interface
between the upper and lower phases. Four volumes of methanol were again
added, and the samples were vortexed. The samples were centrifuged at
16,000 × g for 5 min, and the supernatant was removed without disturbing
the pellet. The protein pellets in each sample were solubilized in an in-
solution digest buffer consisting of 0.5% sodium deoxycholate, 12 mM so-
dium lauroyl sarcosinate, and 50 mM triethylammonium bicarbonate (TEAB).
Samples were heated for 5 min at 95 °C, and the protein concentrations
were measured using the Pierce BCA Protein Assay Kit (Thermo Fisher Sci-
entific). Protein disulfides were then reduced with 5 mM Tris(2-carboxyethyl)
phosphine (TCEP) in 50 mM TEAB for 30 min at room temperature and
alkylated with 10 mM iodoacetamide in 50 mM TEAB for 30 min at room
temperature in the dark. Protein solutions were diluted fivefold with 50 mM
TEAB. Lyophilized porcine trypsin (Promega) was solubilized in 50 mM TEAB
and was used in a mass ratio of 1:100 (trypsin:protein) for a double enzy-
matic digestion of 4 h and then 16 h at 37 °C. Sodium deoxycholate was
precipitated from the peptide solutions with trifluoroacetic acid at a final
concentration of 0.5%. The samples were then centrifuged at 16,000 × g for
5 min, and the supernatant was transferred into new tubes before lyophi-
lization in a centrifugal evaporator. The samples were reconstituted in
100 μL of a buffer solution (2% acetonitrile, 0.5% acetic acid) and desalted
with C18 stage tips as previously described elsewhere (83). Eluted samples
were lyophilized and solubilized with 10 μL of 2% acetonitrile, 0.1% formic
acid and then were placed into injection vials for MS analysis.
The samples were analyzed with an Eksigent 2D nanoLC system attached
to a Q-Exactive Plus (Thermo Fisher Scientific). Peptides were injected into a
laser-pulled nanobore 20 cm × 1.8 μm C18 column (AcuTech Scientific) in
buffer A (2% acetonitrile, 0.15% formic acid) and were eluted using a 3-h
linear gradient from 3 to 80% buffer B (98% acetonitrile, 0.15% formic
acid). The Q-Exactive Plus was operated in Full MS/dd-MS2 mode with a
resolution of 70,000 and an auto gain control target of 3e6 for the parent
scan. The top 20 ions above +1 charge were subjected to higher collision
dissociation (HCD) set to a value of 30 with a resolution of 17,500 and an
auto gain control target of 1e5 as well as a dynamic exclusion of 15 s.
Tandem mass spectrometry data were matched to a protein fasta file
(UniProt-Human 20161005; 21,047 sequences; 11,462,872 residues) using
Mascot software (Matrix Sciences). Identified proteins ordered by expo-
nentially modified protein abundance index (emPAI) are listed in Dataset S1.
emPAI offers approximate, label-free, relative quantitation of the proteins
in the mixture based on protein coverage by the peptide matches in the
database search result. All ex vivo extracts were enriched in TTR but also
contained a mixture of other proteins, with the consistent presence of serum
amyloid-P component, myosin, collagen, and a TRAJ56 fragment.
Western Blot of TTR from ex Vivo Material. Equal amounts of total protein
were loaded and separated by electrophoresis under denaturing conditions
and immunoblotted with polyclonal anti-human TTR (1:10,000; DAKO, Agilent
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Technologies) or anti-truncated TTR obtained from Gunilla Westermark
(1:5,000). HRP-conjugated goat anti-rabbit secondary antibody was diluted to
1:5,000, and SuperSignal West Pico Chemiluminescent Substrate (Thermo
Fisher Scientific) was used to detect TTR as described by the manufacturer.
Recombinant TTR Preparation. Recombinant protein preparations were
obtained as described previously (25). Briefly, Escherichia coli-expressed
proteins were purified by affinity in a HisTrap column (GE Healthcare Life
Science). Peak fractions were combined and further purified by size exclu-
sion on a Superdex S75 prep grade column (GE Healthcare Life Science). Final
samples were stored in 10 mM sodium phosphate (pH 7.5), 100 mM KCl, and
1 mM EDTA at −20 °C.
Nonseeded TTR Aggregation Assay. TTR aggregation assays are described
elsewhere (25). Briefly, 1 mg/mL TTR sample in 10 mM sodium acetate (pH 4.3),
100 mM KCl, and 1 mM EDTA was incubated at 37 °C for a maximum of 4 d.
Protein aggregation was followed by absorbance at 400 nm, anti-TTR immuno-
dot blot of the insoluble fraction, and/or TEM.
Amyloid Seeding Assays. Fibril extracts were used to seed the formation of new
aggregates from recombinant TTR. To further purify the extracts, we treated
them with 1% sodium dodecyl sulfate, and the soluble fraction was discarded
after centrifugation at 13,000 rpm for 5 min (rotor FA-24x2, Eppendorf). This
process was repeated two times, and soluble fractions were discarded. The
sample was washed with 10 mM sodium acetate (pH 7.5), 100 mM KCl, and
1mMEDTA three times by centrifugation and thenwas sonicated in cycles of 5 s
on/5 s off for a total of 10 min at the minimum intensity (18%). The protein
content was measured using the Pierce BCA Protein Assay Kit (Thermo Fisher
Scientific). Seedswere added to 0.5mg/mL recombinant TTR in a final volumeof
200 μL of 5 μMThT, 10mM sodium acetate (pH 4.3 or pH 7.4), 100 mMKCl, and
1 mM EDTA. Unless labeled otherwise, cardiac seeds were analyzed at a con-
centration of 30 ng/μL. ThT fluorescence emission was measured at 482 nm
with absorption at 440 nm in a Varioskan Flash reader (Thermo Fisher Scien-
tific) or a FLUOstar Omega (BMG LabTech) microplate reader. Plates were in-
cubated at 37 °C for 20–72 h as labeled with cycles of 9 min shaking (700 rpm
double orbital) and 1 min rest throughout the incubation. Measurements were
taken every 10 min (bottom read) with automatic gain if read in a Varioskan
Flash reader or with a manual gain of 1,000 if read in a FLUOstar Omega micro-
plate reader. We normalized all our assays to a reference positive control included
in every run. Figures show ThT signal in arbitrary units (a.u.). Fibril formation was
confirmed by TEM. The insoluble fraction was extracted by two cycles of centri-
fugation and final resuspension with 6 M guanidinium hydrochloride. Soluble
fractions were saved from the first centrifugation cycle, and protein concen-
tration was measured by the Pierce BCA protein assay kit (Thermo Fisher Sci-
entific). Absorbance at 280 nm of insoluble fractions was measured in
absorbance units (AU) in a BioPhotometer UV/Vis spectrophotometer (Eppen-
dorf) or in a Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific).
Insoluble and soluble fractions were further analyzed by immunoblots.
Ex Vivo Extract Immunodepletion of TTR Fibrils. TTR fibrils were depleted from
ex vivo extract by immunoreaction to anti-TTR microplate strips from the
Prealbumin ELISA kit (Abcam) as follows. A 100-μL sample containing 1.2 μg/μL
ATTR-D38A was added to an anti-TTR–precoated well and incubated at room
temperature for 30 min. The sample was transferred to a new well and in-
cubated again at room temperature for 30 min. This procedure was repeated
eight times. After every incubation, 5-μL aliquots were transferred to test
tubes and saved. A 5-μL aliquot was also collected from the original sample,
before incubation. The amyloid seeding assay was performed as described
above. Collected samples were added to 0.5 mg/mL recombinant wild-type
TTR in a final volume of 200 μL, and ThT fluorescence was read every 10 min
for 24 h in a FLUOstar Omega microplate with a manual gain of 1,000. Optic
micrographs of resulting aggregates were taken after incubation using a
Celigo S Imaging system under bright-field and UV channels.
Immuno-Dot Blot Analysis. TTR aggregation was visualized by dot-blot
analysis as described previously (25). The insoluble fraction of the samples
was obtained by cycles of centrifugation as described above and dotted onto
nitrocellulose membranes (0.2 μm; Bio-Rad). TTR was observed by using
HisProbe (Thermo Scientific Fisher) or polyclonal rabbit anti-human TTR
(DAKO, Agilent Technologies) antibodies at a concentration of 1:10,000.
Design of Aggregation Blockers. The first generation of TTR aggregation
blockers was designed to bind strands F and H as described previously (25).
They shared a 12-residue-long wild-type sequence with the addition of an N-
methyl group and a four-residue arginine tag. The use of the nonnatural N-
methyl groups to protect aggregation blockers from proteolysis has been
reported elsewhere (81). The addition of a poly-arginine tag confers higher
solubility that is presumed to hinder self-aggregation. These peptides were
further optimized in silico to decrease potential self-association. Two in silico
optimization strategies were performed. (i) Each residue of each peptide was
subsequently substituted by arginine, and (ii) the overall composition of the
peptides was maintained, but the order of residues was changed. The overall
propensity of every sequence to form steric zippers was calculated by the
algorithm ZipperDB, developed previously (84). ZipperDB calculates the pro-
pensity of each six-residue segment of any given sequence to form steric
zippers. The predicted full-atom energies of interactions across the zipper
interface formed by possible self-association for each peptide inhibitor are
shown in SI Appendix, Table S3. We found that arginine substitutions did not
result in a significant energy difference (SI Appendix, Table S3A). Sequence
swapping resulted in peptide sequences with the highest energy scores, which
were less prone to aggregate. The C-terminal residue of F15 was eliminated to
obtain a higher energy score, resulting in TabF2. The optimized inhibitors
were then selected and tested in vitro.
The best-scoring peptides were evaluated in vitro for their efficacy at
inhibiting amyloid seeding (SI Appendix, Fig. S6 and Table S3B). Amyloid
seeding assays were performed as described above. Peptide (180 μM) was
added to 0.5 mg/mL recombinant wild-type TTR and 30 ng/μL ATTR-D38A
seeds. Amyloid seeding was measured after 24 h of incubation at 37 °C by
ThT fluorescence. The ThT signal obtained in the absence of peptide was
considered 100%. The best two inhibitors, TabF2 (RRRRHVAHPFV-N-me-Glu-
FTE) and TabH2 (RRRRSYVTNPTSY-N-me-Ala-VT), were selected for further
analysis and used as a mixture, referred to herein as “TabFH2.”
Statistical Analysis. Statistical analysis of absorbance, TTR aggregation, and
ThT signal was performed with Prism 7 for Mac (GraphPad Software) using an
unpaired t test. All samples were included in the analysis. All quantitative
experiments are presented as independent replicates or as means ± SD of at
least three independent experiments.
Data and Materials Availability. The authors declare that all data generated or
analyzed during this study that support the findings are available within this
published article and its SI Appendix files.
ACKNOWLEDGMENTS. We thank Dr. Michael Sawaya for X-ray fibril diffrac-
tion studies, Dr. Jeffery Kelly for a gift of tafamidis and discussions, Dr. Gunilla
Westermark for the gift of anti-fragmented TTR antibody 1898 and discus-
sions, Drs. Joel Buxbaum and Duilio Cascio for helpful discussions, Dr. James
LeBlanc and Dr. Daniel Anderson for technical support, Dr. Sarah Dry for
assistance in collecting and storing specimens, Steve Yu for his help on
electron microscopy, and the patients who generously donated tissues. This
work was supported by the Amyloidosis Foundation, the NIH, the Depart-
ment of Energy, and The Howard Hughes Medical Institute.
1. Holmes BB, et al. (2014) Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl
Acad Sci USA 111:E4376–E4385.
2. Meyer-LuehmannM, et al. (2006) Exogenous induction of cerebral beta-amyloidogenesis
is governed by agent and host. Science 313:1781–1784.
3. Marin-Argany M, et al. (2016) Cell damage in light chain amyloidosis: Fibril in-
ternalization, toxicity and cell-mediated seeding. J Biol Chem 291:19813–19825.
4. Kisilevsky R, Boudreau L (1983) Kinetics of amyloid deposition. I. The effects of
amyloid-enhancing factor and splenectomy. Lab Invest 48:53–59.
5. Pomfret EA, et al. (1998) Effect of orthotopic liver transplantation on the progression
of familial amyloidotic polyneuropathy. Transplantation 65:918–925.
6. Costa PP, Figueira AS, Bravo FR (1978) Amyloid fibril protein related to pre-
albumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA 75:
4499–4503.
7. Sletten K, Westermark P, Natvig JB (1980) Senile cardiac amyloid is related to pre-
albumin. Scand J Immunol 12:503–506.
8. Benson MD (1981) Partial amino acid sequence homology between an heredofamilial
amyloid protein and human plasma prealbumin. J Clin Invest 67:1035–1041.
9. PrasM, Prelli F, Franklin EC, Frangione B (1983) Primary structure of an amyloid prealbumin
variant in familial polyneuropathy of Jewish origin. Proc Natl Acad Sci USA 80:539–542.
10. Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349:
583–596.
11. Hurshman Babbes AR, Powers ET, Kelly JW (2008) Quantification of the thermodynam-
ically linked quaternary and tertiary structural stabilities of transthyretin and its disease-
associated variants: The relationship between stability and amyloidosis. Biochemistry 47:
6969–6984.
12. Benson MD (2012) Pathogenesis of transthyretin amyloidosis. Amyloid 19:14–15.
Saelices et al. PNAS | vol. 115 | no. 29 | E6749
BI
O
CH
EM
IS
TR
Y
PN
A
S
PL
U
S
13. Gorevic PD, Prelli FC, Wright J, Pras M, Frangione B (1989) Systemic senile amyloidosis.
Identification of a new prealbumin (transthyretin) variant in cardiac tissue: Immu-
nologic and biochemical similarity to one form of familial amyloidotic poly-
neuropathy. J Clin Invest 83:836–843.
14. Westermark P, Bergström J, Solomon A, Murphy C, Sletten K (2003) Transthyretin-
derived senile systemic amyloidosis: Clinicopathologic and structural considerations.
Amyloid 10:48–54.
15. Su Y, et al. (2011) Transthyretin-derived amyloid deposition in the heart of an elderly
Japanese population. Amyloid 18:180–181.
16. Ihse E, Suhr OB, Hellman U, Westermark P (2011) Variation in amount of wild-type
transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med (Berl)
89:171–180.
17. Yazaki M, et al. (2000) Cardiac amyloid in patients with familial amyloid poly-
neuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res
Commun 274:702–706.
18. Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN (2004) Tissue damage in the
amyloidoses: Transthyretin monomers and nonnative oligomers are the major cyto-
toxic species in tissue culture. Proc Natl Acad Sci USA 101:2817–2822.
19. Bergström J, et al. (2005) Amyloid deposits in transthyretin-derived amyloidosis:
Cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 206:
224–232.
20. Benson MD (2012) Amyloid and Related Disorders, eds Picken MM, Dogan A (Hu-
mana, Herrera, GA), pp 53–67.
21. Benson MD (2013) Liver transplantation and transthyretin amyloidosis. Muscle Nerve
47:157–162.
22. Stangou AJ, et al. (1998) Progressive cardiac amyloidosis following liver trans-
plantation for familial amyloid polyneuropathy: Implications for amyloid fibrillo-
genesis. Transplantation 66:229–233.
23. Stangou AJ, Hawkins PN (2004) Liver transplantation in transthyretin-related familial
amyloid polyneuropathy. Curr Opin Neurol 17:615–620.
24. Eisenberg D, Jucker M (2012) The amyloid state of proteins in human diseases. Cell
148:1188–1203.
25. Saelices L, et al. (2015) Uncovering the mechanism of aggregation of human trans-
thyretin. J Biol Chem 290:28932–28943.
26. Nelson R, et al. (2005) Structure of the cross-beta spine of amyloid-like fibrils. Nature
435:773–778.
27. Westermark P, Sletten K, Johansson B, Cornwell GG, 3rd (1990) Fibril in senile systemic
amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 87:
2843–2845.
28. Foss TR, Wiseman RL, Kelly JW (2005) The pathway by which the tetrameric protein
transthyretin dissociates. Biochemistry 44:15525–15533.
29. Jiang X, et al. (2001) An engineered transthyretin monomer that is non-
amyloidogenic, unless it is partially denatured. Biochemistry 40:11442–11452.
30. Hurshman AR, White JT, Powers ET, Kelly JW (2004) Transthyretin aggregation under
partially denaturing conditions is a downhill polymerization. Biochemistry 43:
7365–7381.
31. Galant NJ, Westermark P, Higaki JN, Chakrabartty A (2017) Transthyretin amyloidosis:
An under-recognized neuropathy and cardiomyopathy. Clin Sci (Lond) 131:395–409.
32. Damy T, et al. (2016) Clinical, ECG and echocardiographic clues to the diagnosis of
TTR-related cardiomyopathy. Open Heart 3:e000289.
33. Rapezzi C, et al. (2013) Disease profile and differential diagnosis of hereditary
transthyretin-related amyloidosis with exclusively cardiac phenotype: An Italian per-
spective. Eur Heart J 34:520–528.
34. Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW (2004) Diflunisal ana-
logues stabilize the native state of transthyretin. Potent inhibition of amyloido-
genesis. J Med Chem 47:355–374.
35. Bulawa CE, et al. (2012) Tafamidis, a potent and selective transthyretin kinetic sta-
bilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 109:9629–9634.
36. Werdelin O, Ranlov P (1966) Amyloidosis in mice produced by transplantation of
spleen cells from casein-treated mice. Acta Pathol Microbiol Scand 68:1–18.
37. Ranlov P (1967) The adoptive transfer of experimental mouse amyloidosis by in-
travenous injections of spleen cell extracts from casein-treated syngeneic donor mice.
Acta Pathol Microbiol Scand 70:321–335.
38. Hardt F, Ranlov P (1968) Transfer amyloidosis. Local and systemic amyloidosis in re-
cipients of syngeneic spleen grafts from non-amyloidotic, casein-sensitized donor
mice. Acta Pathol Microbiol Scand 73:549–558.
39. Wanstrup J, Ranlov P (1968) Transfer amyloidosis: Ultrastructure of the transferred
subcellular fractions. Acta Pathol Microbiol Scand 74:303–304.
40. Kisilevsky R, Axelrad M (1976) The pathogenesis of amyloid deposition: A new hy-
pothesis. Med Hypotheses 2:233–237.
41. Kisilevsky R, Axelrad M, Corbett W, Brunet S, Scott F (1977) The role of inflammatory
cells in the pathogenesis of amyloidosis. Lab Invest 37:544–553.
42. Axelrad MA, Kisilevsky R, Willmer J, Chen SJ, Skinner M (1982) Further characteriza-
tion of amyloid-enhancing factor. Lab Invest 47:139–146.
43. Jarrett JT, Lansbury PTJ, Jr (1993) Seeding “one-dimensional crystallization” of amy-
loid: A pathogenic mechanism in Alzheimer’s disease and scrapie? Cell 73:1055–1058.
44. Bessen RA, et al. (1995) Non-genetic propagation of strain-specific properties of
scrapie prion protein. Nature 375:698–700.
45. Petkova AT, et al. (2005) Self-propagating, molecular-level polymorphism in Alzheimer’s
beta-amyloid fibrils. Science 307:262–265.
46. Colby DW, et al. (2007) Prion detection by an amyloid seeding assay. Proc Natl Acad
Sci USA 104:20914–20919.
47. Paravastu AK, Qahwash I, Leapman RD, Meredith SC, Tycko R (2009) Seeded growth
of beta-amyloid fibrils from Alzheimer’s brain-derived fibrils produces a distinct fibril
structure. Proc Natl Acad Sci USA 106:7443–7448.
48. Lu JX, et al. (2013) Molecular structure of β-amyloid fibrils in Alzheimer’s disease brain
tissue. Cell 154:1257–1268.
49. Saborio GP, Permanne B, Soto C (2001) Sensitive detection of pathological prion
protein by cyclic amplification of protein misfolding. Nature 411:810–813.
50. Castilla J, Saá P, Hetz C, Soto C (2005) In vitro generation of infectious scrapie prions.
Cell 121:195–206.
51. Prusiner SB (2012) Cell biology. A unifying role for prions in neurodegenerative dis-
eases. Science 336:1511–1513.
52. Goedert M (2015) Neurodegeneration. Alzheimer’s and Parkinson’s diseases: The
prion concept in relation to assembled Aβ, tau, and α-synuclein. Science 349:1255555.
53. Goedert M, Eisenberg DS, Crowther RA (2017) Propagation of tau aggregates and
neurodegeneration. Annu Rev Neurosci 40:189–210.
54. Goedert M, Jakes R, Spillantini MG (2017) The synucleinopathies: Twenty years on on.
J Parkinsons Dis 7(Suppl 1):S53–S71.
55. Clavaguera F, et al. (2009) Transmission and spreading of tauopathy in transgenic
mouse brain. Nat Cell Biol 11:909–913.
56. Desplats P, et al. (2009) Inclusion formation and neuronal cell death through neuron-
to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 106:13010–13015.
57. Brown P, et al. (2012) Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg
Infect Dis 18:901–907.
58. Colon W, Kelly JW (1992) Partial denaturation of transthyretin is sufficient for amy-
loid fibril formation in vitro. Biochemistry 31:8654–8660.
59. Tagoe CE, French D, Gallo G, Buxbaum JN (2004) Amyloidogenesis is neither
accelerated nor enhanced by injections of preformed fibrils in mice transgenic for
wild-type human transthyretin: The question of infectivity. Amyloid 11:21–26.
60. Wei L, et al. (2004) Deposition of transthyretin amyloid is not accelerated by the same
amyloid in vivo. Amyloid 11:113–120.
61. Liepnieks JJ, Benson MD (2007) Progression of cardiac amyloid deposition in heredi-
tary transthyretin amyloidosis patients after liver transplantation. Amyloid 14:
277–282.
62. Carvalho A, Rocha A, Lobato L (2015) Liver transplantation in transthyretin amy-
loidosis: Issues and challenges. Liver Transpl 21:282–292.
63. Lladó L, et al. (2010) Risk of transmission of systemic transthyretin amyloidosis after
domino liver transplantation. Liver Transpl 16:1386–1392.
64. Buxbaum JN, et al. (2012) Why are some amyloidoses systemic? Does hepatic
“chaperoning at a distance” prevent cardiac deposition in a transgenic model of
human senile systemic (transthyretin) amyloidosis? FASEB J 26:2283–2293.
65. Misumi Y, et al. (2016) Recipient aging accelerates acquired transthyretin amyloidosis
after domino liver transplantation. Liver Transpl 22:656–664.
66. Stangou AJ, Heaton ND, Hawkins PN (2005) Transmission of systemic transthyretin
amyloidosis by means of domino liver transplantation. N Engl J Med 352:2356.
67. Westermark GT, Westermark P (2010) Prion-like aggregates: Infectious agents in
human disease. Trends Mol Med 16:501–507.
68. Westermark GT, Fändrich M, Lundmark K, Westermark P (2017) Noncerebral amy-
loidoses: Aspects on seeding, cross-seeding, and transmission. Cold Spring Harb
Perspect Med 8:a024323.
69. Obayashi K, et al. (2011) Amyloid turnover after liver transplantation in FAP. Amyloid
18:187–189.
70. Westermark P, Sletten K, Olofsson BO (1987) Prealbumin variants in the amyloid fi-
brils of Swedish familial amyloidotic polyneuropathy. Clin Exp Immunol 69:695–701.
71. Sievers SA, et al. (2011) Structure-based design of non-natural amino-acid inhibitors
of amyloid fibril formation. Nature 475:96–100.
72. Soragni A, et al. (2016) A designed inhibitor of p53 aggregation rescues p53 tumor
suppression in ovarian carcinomas. Cancer Cell 29:90–103.
73. Ackermann EJ, et al. (2016) Suppressing transthyretin production in mice, monkeys
and humans using 2nd-generation antisense oligonucleotides. Amyloid 23:148–157.
74. Ackermann EJ, et al. (2012) Clinical development of an antisense therapy for the
treatment of transthyretin-associated polyneuropathy. Amyloid 19:43–44.
75. Coelho T, et al. (2013) Safety and efficacy of RNAi therapy for transthyretin amy-
loidosis. N Engl J Med 369:819–829.
76. Sekijima Y, Tojo K, Morita H, Koyama J, Ikeda S (2015) Safety and efficacy of long-
term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis.
Amyloid 22:79–83.
77. Higaki JN, et al. (2016) Novel conformation-specific monoclonal antibodies against
amyloidogenic forms of transthyretin. Amyloid 23:86–97.
78. Hosoi A, et al. (2016) Novel antibody for the treatment of transthyretin amyloidosis.
J Biol Chem 291:25096–25105.
79. Ihse E, et al. (2013) Amyloid fibrils containing fragmented ATTR may be the standard
fibril composition in ATTR amyloidosis. Amyloid 20:142–150.
80. Rodriguez JA, et al. (2015) Structure of the toxic core of α-synuclein from invisible
crystals. Nature 525:486–490.
81. Arvai A (2015) Adxv–A Program to Display X-ray Diffraction Images. Available at
http://www.scripps.edu/∼arvai/adxv.html. Accessed June 15, 2018.
82. Shaw BF, et al. (2008) Detergent-insoluble aggregates associated with amyotrophic
lateral sclerosis in transgenic mice contain primarily full-length, unmodified super-
oxide dismutase-1. J Biol Chem 283:8340–8350.
83. Rappsilber J, Mann M, Ishihama Y (2007) Protocol for micro-purification, enrichment,
pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc
2:1896–1906.
84. Thompson MJ, et al. (2006) The 3D profile method for identifying fibril-forming
segments of proteins. Proc Natl Acad Sci USA 103:4074–4078.
E6750 | www.pnas.org/cgi/doi/10.1073/pnas.1805131115 Saelices et al.
